Insider · CIK 0002015536
Deep Track Biotechnology Master Fund, Ltd.
owner
Files at DVAX (DYNAVAX TECHNOLOGIES CORP), LBRX (LB PHARMACEUTICALS INC). First filing Aug 22, 2025, latest Sep 16, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
1 / 1
$40M bought, $22M sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 50Moderate | LB PHARMACEUTICALS INC | $40M 2,666,666 shares | +389% | - | |
| 42Moderate | DVAXsell DYNAVAX TECHNOLOGIES CORP | $22M 2,065,137 shares | -12% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 12, 2025 | LBRX LB PHARMACEUTICALS INC | CConversion Common Stock | +686,138 | - | - | 686,138 | Sep 16, 2025 |
| Sep 12, 2025 | LBRX LB PHARMACEUTICALS INC | POpen-market purchase Common Stock | +2,000,000 | $15.00 | $30M | 2,686,138 | Sep 16, 2025 |
| Sep 12, 2025 | LBRX LB PHARMACEUTICALS INC | POpen-market purchase Common Stockindirect: By Deep Track Special Opportunities Fund, LP | +666,666 | $15.00 | $10.0M | 666,666 | Sep 16, 2025 |
| Sep 12, 2025 | LBRX LB PHARMACEUTICALS INC | CConversion Series C Preferred Stockderivative | -16,666,667 | - | - | 0 | Sep 16, 2025 |
| Aug 21, 2025 | DVAX DYNAVAX TECHNOLOGIES CORP | SOpen-market sale Common Stock, par value $0.001 per share | -1,094,994 | $11.03 | $12M | 16,696,492 | Aug 22, 2025 |
| Aug 22, 2025 | DVAX DYNAVAX TECHNOLOGIES CORP | SOpen-market sale Common Stock, par value $0.001 per share | -970,143 | $10.59 | $10M | 15,726,349 | Aug 22, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.